奥锐特药业股份有限公司2025年度权益分派实施公告详解
奥锐特药业股份有限公司（证券代码：605116，简称：奥锐特）发布了2025年度权益分派实施公告，内容涉及分红方案、相关日期、差异化分红政策、税务处理等重要信息，需股东高度关注。
一、分红方案概述
- 每股现金红利为0.34元（含税），以2026年6月12日股权登记日登记在册的股东为对象。
- 本次分红为差异化分红，公司回购专用证券账户中的股份不参与分配。
- 不送红股，不进行资本公积金转增股本。
- 实际参与分配股本为403,406,015股，合计派发现金红利137,158,045.10元（含税）。
- 除权除息参考价为前收盘价减去0.3377元/股（摊薄计算后）。
二、关键日期
- 股权登记日： 2026年6月12日
- 除权（息）日： 2026年6月15日
- 现金红利发放日： 2026年6月15日
三、实施细则
- 无限售条件流通股的红利由中国结算上海分公司通过资金清算系统派发。
- 部分大股东（如浙江桐本投资有限公司、天台铂融投资合伙企业等）红利由公司自行发放。
- 未办理指定交易的股东，红利暂由中国结算上海分公司保管。
四、税务处理细节
- 个人股东及证券投资基金：暂不扣税，实际每股派发0.34元。根据持股期限，转让时代扣个人所得税：持股1月以内全额计入应纳税所得额（20%）、1月以上至1年（含1年）减按50%（10%）、超过1年暂免征收。
- 有限售条件流通股自然人股东：公司代扣10%，实际每股派发0.306元。
- QFII：公司代扣10%企业所得税，实际每股派发0.306元。如需享受税收协定待遇可自行申报。
- 沪港通投资者：公司代扣10%，实际每股派发0.306元。
- 其他机构投资者和法人股东：公司不代扣，实际每股派发0.34元，所得税自行申报缴纳。
五、对投资者的影响与需关注事项
- 本次分红方案通过股东大会审议，具有法律效力，且涉及现金流出，对公司财务状况有一定影响。
- 差异化分红方案，对回购股份不分红，有利于提升分红效率、保护流通股股东权益。
- 除权参考价明确，可能会对股价产生短期波动。
- 税务处理细致，提醒投资者根据自身持股情况合理规划税务。
- 分红总额较大，显示公司盈利能力及现金流充足，可能提升投资者信心。
- 分红方案为现金分红，不涉及股本扩张，长期影响股东结构有限。
六、咨询渠道
如有疑问，可联系奥锐特证券法务部，电话：0576-83170900。
免责声明
本文为财经记者根据奥锐特药业股份有限公司公告整理，仅供投资者参考，不构成任何投资建议。投资者需根据自身情况和公告细节，自行判断投资风险。公司分红方案及相关税务政策以官方公告及国家税务机关规定为准。
Detailed Implementation Announcement of Aorui Pharmaceutical Co., Ltd. 2025 Annual Dividend
Aorui Pharmaceutical Co., Ltd. (Stock code: 605116, short name: Aorui) has released the implementation details of its 2025 annual dividend, covering the distribution plan, key dates, differentiated dividend policy, and tax treatment. Investors should pay close attention to these details.
I. Dividend Plan Overview
- Each share will receive a cash dividend of RMB 0.34 (tax included), targeting shareholders registered as of June 12, 2026.
- This is a differentiated dividend—shares in the company’s repurchase account are excluded from the distribution.
- No bonus shares or capital reserve share increase in this round.
- The actual participating share capital is 403,406,015 shares, totaling RMB 137,158,045.10 in cash dividends (tax included).
- Ex-dividend reference price is previous closing price minus RMB 0.3377/share (post-dilution calculation).
II. Key Dates
- Record Date: June 12, 2026
- Ex-Dividend Date: June 15, 2026
- Dividend Payment Date: June 15, 2026
III. Implementation Details
- Dividends for unrestricted tradable shares will be distributed via Shanghai Clearing House’s financial clearing system.
- Major shareholders such as Zhejiang Tongben Investment Co., Ltd., Tiantai Borong Investment Partnership, etc., will have dividends paid directly by the company.
- Dividends for shareholders who have not designated trading accounts will be held by Shanghai Clearing House until designation is complete.
IV. Tax Treatment
- Individual shareholders and securities investment funds: No withholding at payment, RMB 0.34/share distributed. Tax is withheld upon share transfer based on holding period: within 1 month (20%), 1 month to 1 year (10%), over 1 year (exempt).
- Restricted tradable shares held by individuals: 10% withholding, net RMB 0.306/share.
- QFII: 10% corporate income tax withheld, net RMB 0.306/share. Tax treaty benefits can be applied for post-payment.
- Hong Kong market investors via Shanghai-Hong Kong Connect: 10% withholding, net RMB 0.306/share.
- Other institutional investors and legal entity shareholders: No withholding, RMB 0.34/share paid, tax to be handled by the recipient.
V. Investor Impact & Price-Sensitive Points
- The dividend plan is approved by the general meeting of shareholders and is legally effective, impacting the company’s cash position.
- Differentiated dividend excludes repurchased shares, improving dividend efficiency and protecting tradable shareholders’ interests.
- Clear ex-dividend reference price may cause short-term price fluctuations.
- Detailed tax rules require investors to plan their tax obligations based on their holding period and share type.
- Large total dividend payout demonstrates the company’s profitability and robust cash flow, potentially boosting investor confidence.
- Cash dividend (no bonus shares), limited long-term impact on share structure.
VI. Contact for Inquiry
For questions, contact Aorui Pharmaceutical’s Securities Legal Department at 0576-83170900.
Disclaimer
This article is compiled by a financial reporter based on the official announcement from Aorui Pharmaceutical Co., Ltd., for investor information only. It does not constitute investment advice. Investors should make their own risk assessments based on the official announcement and their individual circumstances. Dividend and tax policies are subject to official announcement and relevant tax authority regulations.
